Literature DB >> 23941829

NAFLD leads to liver cancer: do we have sufficient evidence?

Xiao-Yan Duan1, Lei Zhang2, Jian-Gao Fan3, Liang Qiao4.   

Abstract

Primary liver cancer has several well-recognized risk factors, such as HBV and HCV infection, alcohol abuse and aflatoxin. Recent studies show that nonalcoholic fatty liver disease (NAFLD), especially its aggressive form nonalcoholic steatohepatitis (NASH) is associated with an increased risk of liver cancer, mainly hepatocellular carcinoma (HCC). On the other hand, clinical and epidemiological data have showed that HCC has rarely been found in a "pure" fatty liver in human. Thus, the question we need to ask is do we have sufficient evidence to support a causative role of NAFLD in liver cancer? Furthermore, if NAFLD is indeed a causative factor for liver cancer, what is the mechanism? Perhaps at this stage, fatty liver and NASH can be regarded as a definite risk factor for liver cancer, but to conclude that NAFLD induces HCC requires more robust in vitro and in vivo data.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fatty liver; Hepatocellular carcinoma; Liver cancer; Nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2013        PMID: 23941829     DOI: 10.1016/j.canlet.2013.07.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

Review 1.  Pesticide exposure and liver cancer: a review.

Authors:  Trang VoPham; Kimberly A Bertrand; Jaime E Hart; Francine Laden; Maria M Brooks; Jian-Min Yuan; Evelyn O Talbott; Darren Ruddell; Chung-Chou H Chang; Joel L Weissfeld
Journal:  Cancer Causes Control       Date:  2017-02-13       Impact factor: 2.506

2.  NAFLD-which patients should have hepatocellular carcinoma surveillance?

Authors:  Zeynep C Elcioglu; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

3.  Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression.

Authors:  Shukun Han; Bing Han; Zhongmin Li; Du Sun
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

4.  FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients.

Authors:  Nozomi Kawata; Hirokazu Takahashi; Shinji Iwane; Kanako Inoue; Motoyasu Kojima; Michiko Kohno; Kenichi Tanaka; Hitoe Mori; Hiroshi Isoda; Satoshi Oeda; Yayoi Matsuda; Yoshiaki Egashira; Jyunichi Nojiri; Hiroyuki Irie; Yuichiro Eguchi; Keizo Anzai
Journal:  Diabetol Int       Date:  2020-07-09

5.  Prognostic gene biomarker identification in liver cancer by data mining.

Authors:  Gang Liu; Haitao Tang; Chen Li; Haiyan Zhen; Zhigang Zhang; Yongzhong Sha
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Quantitative analysis of the murine lipid droplet-associated proteome during diet-induced hepatic steatosis.

Authors:  Salmaan Ahmed Khan; Edith E Wollaston-Hayden; Todd W Markowski; LeeAnn Higgins; Douglas G Mashek
Journal:  J Lipid Res       Date:  2015-09-28       Impact factor: 5.922

Review 7.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

8.  Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.

Authors:  Xinli Li; Chun Liu; Blanche C Ip; Kang-Quan Hu; Donald E Smith; Andrew S Greenberg; Xiang-Dong Wang
Journal:  J Exp Clin Cancer Res       Date:  2015-11-11

Review 9.  Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development.

Authors:  Thomas Tu; Magdalena A Budzinska; Annette E Maczurek; Robert Cheng; Anna Di Bartolomeo; Fiona J Warner; Geoffrey W McCaughan; Susan V McLennan; Nicholas A Shackel
Journal:  Int J Mol Sci       Date:  2014-05-27       Impact factor: 5.923

Review 10.  Leptin signaling molecular actions and drug target in hepatocellular carcinoma.

Authors:  Nan Jiang; Rongtong Sun; Qing Sun
Journal:  Drug Des Devel Ther       Date:  2014-11-14       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.